Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
An erratum to this article was published (Ann Rheum Dis, Nov 2023 ↗)
Main finding · MACEResult — go to the resultHRw 1.0 95% CI 0.7–1.5Authors' conclusion
This study provides reassuring data regarding the risks of MACEs and VTEs in patients initiating a JAKi versus adalimumab, including patients at high risk of cardiovascular diseases.
Study context
- Population
- Patients with RA with first dispensation of a Janus kinase inhibitor (JAKi) or adalimumab between 1 July 2017 and 31 May 2021, French national health data system
- Participants
- 15,835 patients
- Exposure
- JAKi vs adalimumab
- JAKin = 8,481
- Adalimumabn = 7,354reference
- Outcome
- Occurrence of a MACE or VTE
Methodological detailsinverse probability of treatment weighting, methotrexate as a time-varying variable
- Inverse probability of treatment weighting
- Methotrexate as a time-varying variable
Main finding
MACE
HRw
1.0
95% CI 0.7–1.5
P = 0.99
Events by group
Exposed
54
events
Non-exposed
35
events
As reported in the abstract
Observational data: associations, not effects.
Further findings
Patients aged ≥65 years with at least one cardiovascular risk factor (subgroup)
- Results consistent, despite a lack of power
Safety
Events
| Outcome | Exposed | Non-exposed | HRw (CI) | P value |
|---|---|---|---|---|
| VTE (co-primary endpoint)Inverse probability of treatment weighting | 75 | 32 | 1.1 (0.7–1.6) | P = 0.63 |
- VTE (co-primary endpoint): Exposed = JAKi initiators; non-exposed = adalimumab initiators
Original publication
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. Published 5 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →